

## **Clinical Guidelines and Related Provider Requirements: Pharmacologic Treatment of Schizophrenia**

Community Behavioral Health (CBH) has adopted Clinical Practice Guidelines (CPGs) to outline best practices for the treatment of specific disorders or certain populations. These guidelines will be used by CBH to assess the quality of care provided to CBH members. As such, providers are advised to review and, where appropriate, implement these best practices in their care. CPGs apply to all clinical settings where care is delivered to members. CPGs should be used in conjunction with any level-of-care-specific performance standards, as well as all other required CBH, NIAC, state, and federal regulations and standards.

CBH has updated the existing guidelines for the pharmacologic treatment of schizophrenia. The most recent versions of all CPGs can now be found on the [Clinical Practice Guidelines webpage](#).

To ensure alignment and best practices, CBH recommends that providers review the CPGs and make any necessary updates or revisions to provider policies and procedures.

Adherence to the CPGs will be assessed through CBH monitoring and oversight, including Quality, Clinical, and Compliance Department protocols. Additionally, components may be reviewed as part of the Network Improvement and Accountability Collaborative (NIAC) initial and recredentialing reviews. To assess quality of care and align with state and regulatory requirements, CBH will also be utilizing several specific metrics for the CPG, which are detailed in the table below.

<i>Clinical Guidelines</i>	<i>Quality Metrics</i>
<a href="#"><u>Clinical Practice Guidelines for the Pharmacologic Treatment of Schizophrenia</u></a>	<ul style="list-style-type: none"> <li>➔ <a href="#"><u>HEDIS SAA: Adherence to Antipsychotic Medications for Individuals with Schizophrenia</u></a></li> <li>➔ <a href="#"><u>HEDIS SSD: Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications</u></a></li> <li>➔ <a href="#"><u>HEDIS SMD: Diabetes Monitoring for People with Diabetes and Schizophrenia</u></a></li> </ul>

These requirements take effect on June 1, 2023. Please direct questions regarding *Clinical Guidelines for the Pharmacologic Treatment of Schizophrenia* to [stephanie.byers@phila.gov](mailto:stephanie.byers@phila.gov).